Polyphenols synergistic drugs to ameliorate non-alcoholic fatty liver disease via signal pathway and gut microbiota: A review

Background: Non-alcoholic fatty liver disease (NAFLD) is a common chronic liver disease with an increasing incidence worldwide. Single drug therapy may have toxic side effects and disrupt gut microbiota balance. Polyphenols are widely used in disease intervention due to their distinctive nutritional...

Full description

Saved in:
Bibliographic Details
Main Authors: Hongcai Li, Jingjing Liang, Mengzhen Han, Zhenpeng Gao
Format: Article
Language:English
Published: Elsevier 2025-02-01
Series:Journal of Advanced Research
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2090123224000912
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832595740710404096
author Hongcai Li
Jingjing Liang
Mengzhen Han
Zhenpeng Gao
author_facet Hongcai Li
Jingjing Liang
Mengzhen Han
Zhenpeng Gao
author_sort Hongcai Li
collection DOAJ
description Background: Non-alcoholic fatty liver disease (NAFLD) is a common chronic liver disease with an increasing incidence worldwide. Single drug therapy may have toxic side effects and disrupt gut microbiota balance. Polyphenols are widely used in disease intervention due to their distinctive nutritional properties and medicinal value, which a potential gut microbiota modulator. However, there is a lack of comprehensive review to explore the efficacy and mechanism of combined therapy with drugs and polyphenols for NAFLD. Aim of review: Based on this, this review firstly discusses the link between NAFLD and gut microbiota, and outlines the effects of polyphenols and drugs on gut microbiota. Secondly, it examined recent advances in the treatment and intervention of NAFLD with drugs and polyphenols and the therapeutic effect of the combination of the two. Finally, we highlight the underlying mechanisms of polyphenol combined drug therapy in NAFLD. This is mainly in terms of signaling pathways (NF-κB, AMPK, Nrf2, JAK/STAT, PPAR, SREBP-1c, PI3K/Akt and TLR) and gut microbiota. Furthermore, some emerging mechanisms such as microRNA potential biomarker therapies may provide therapeutic avenues for NAFLD. Key scientific concepts of review: Drawing inspiration from combination drug strategies, the use of active substances in combination with drugs for NAFLD intervention holds transformative and prospective potential, both improve NAFLD and restore gut microbiota balance while reducing the required drug dosage. This review systematically discusses the bidirectional interactions between gut microbiota and NAFLD, and summarizes the potential mechanisms of polyphenol synergistic drugs in the treatment of NAFLD by modulating signaling pathways and gut microbiota. Future researches should develop multi-omics technology to identify patients who benefit from polyphenols combination drugs and devising individualized treatment plans to enhance its therapeutic effect.
format Article
id doaj-art-24de0a607aaf4c00bf690e4a57319b8a
institution Kabale University
issn 2090-1232
language English
publishDate 2025-02-01
publisher Elsevier
record_format Article
series Journal of Advanced Research
spelling doaj-art-24de0a607aaf4c00bf690e4a57319b8a2025-01-18T05:04:23ZengElsevierJournal of Advanced Research2090-12322025-02-01684362Polyphenols synergistic drugs to ameliorate non-alcoholic fatty liver disease via signal pathway and gut microbiota: A reviewHongcai Li0Jingjing Liang1Mengzhen Han2Zhenpeng Gao3College of Food Science and Engineering, Northwest A&F University, 712100 Yangling, Shaanxi, People’s Republic of ChinaCollege of Food Science and Engineering, Northwest A&F University, 712100 Yangling, Shaanxi, People’s Republic of ChinaCollege of Food Science and Engineering, Northwest A&F University, 712100 Yangling, Shaanxi, People’s Republic of ChinaCorresponding author.; College of Food Science and Engineering, Northwest A&F University, 712100 Yangling, Shaanxi, People’s Republic of ChinaBackground: Non-alcoholic fatty liver disease (NAFLD) is a common chronic liver disease with an increasing incidence worldwide. Single drug therapy may have toxic side effects and disrupt gut microbiota balance. Polyphenols are widely used in disease intervention due to their distinctive nutritional properties and medicinal value, which a potential gut microbiota modulator. However, there is a lack of comprehensive review to explore the efficacy and mechanism of combined therapy with drugs and polyphenols for NAFLD. Aim of review: Based on this, this review firstly discusses the link between NAFLD and gut microbiota, and outlines the effects of polyphenols and drugs on gut microbiota. Secondly, it examined recent advances in the treatment and intervention of NAFLD with drugs and polyphenols and the therapeutic effect of the combination of the two. Finally, we highlight the underlying mechanisms of polyphenol combined drug therapy in NAFLD. This is mainly in terms of signaling pathways (NF-κB, AMPK, Nrf2, JAK/STAT, PPAR, SREBP-1c, PI3K/Akt and TLR) and gut microbiota. Furthermore, some emerging mechanisms such as microRNA potential biomarker therapies may provide therapeutic avenues for NAFLD. Key scientific concepts of review: Drawing inspiration from combination drug strategies, the use of active substances in combination with drugs for NAFLD intervention holds transformative and prospective potential, both improve NAFLD and restore gut microbiota balance while reducing the required drug dosage. This review systematically discusses the bidirectional interactions between gut microbiota and NAFLD, and summarizes the potential mechanisms of polyphenol synergistic drugs in the treatment of NAFLD by modulating signaling pathways and gut microbiota. Future researches should develop multi-omics technology to identify patients who benefit from polyphenols combination drugs and devising individualized treatment plans to enhance its therapeutic effect.http://www.sciencedirect.com/science/article/pii/S2090123224000912Non-alcoholic fatty liver diseaseGut-liver conductionIndividualized treatmentMechanism
spellingShingle Hongcai Li
Jingjing Liang
Mengzhen Han
Zhenpeng Gao
Polyphenols synergistic drugs to ameliorate non-alcoholic fatty liver disease via signal pathway and gut microbiota: A review
Journal of Advanced Research
Non-alcoholic fatty liver disease
Gut-liver conduction
Individualized treatment
Mechanism
title Polyphenols synergistic drugs to ameliorate non-alcoholic fatty liver disease via signal pathway and gut microbiota: A review
title_full Polyphenols synergistic drugs to ameliorate non-alcoholic fatty liver disease via signal pathway and gut microbiota: A review
title_fullStr Polyphenols synergistic drugs to ameliorate non-alcoholic fatty liver disease via signal pathway and gut microbiota: A review
title_full_unstemmed Polyphenols synergistic drugs to ameliorate non-alcoholic fatty liver disease via signal pathway and gut microbiota: A review
title_short Polyphenols synergistic drugs to ameliorate non-alcoholic fatty liver disease via signal pathway and gut microbiota: A review
title_sort polyphenols synergistic drugs to ameliorate non alcoholic fatty liver disease via signal pathway and gut microbiota a review
topic Non-alcoholic fatty liver disease
Gut-liver conduction
Individualized treatment
Mechanism
url http://www.sciencedirect.com/science/article/pii/S2090123224000912
work_keys_str_mv AT hongcaili polyphenolssynergisticdrugstoamelioratenonalcoholicfattyliverdiseaseviasignalpathwayandgutmicrobiotaareview
AT jingjingliang polyphenolssynergisticdrugstoamelioratenonalcoholicfattyliverdiseaseviasignalpathwayandgutmicrobiotaareview
AT mengzhenhan polyphenolssynergisticdrugstoamelioratenonalcoholicfattyliverdiseaseviasignalpathwayandgutmicrobiotaareview
AT zhenpenggao polyphenolssynergisticdrugstoamelioratenonalcoholicfattyliverdiseaseviasignalpathwayandgutmicrobiotaareview